Previous 10 | Next 10 |
We highlighted three things the bulls needed to be worried about in 2022 the last time we covered Viatris. Our data to date suggests that guidance is likely to suffer, and Q2 should be where it happens. There is some encouraging news for 2023 and that helps the long case. ...
In 2015, I started publishing quarterly updates regarding my dividend growth portfolio. I believe that someone who writes about financial assets should share his main holdings with his readers. In this article, I will share my portfolio, changes in the past 3 months and stocks tha...
In my portfolio, I have five groups: Dividend growth, value, REIT, high yield, and growth. In today's article, I will talk about dividend growth and high yield stocks. There are rules I use to take out emotions of my decisions. For further details see: My Portfolio - Par...
One year from the March 2020 lows, this article takes a look back at the worst-performing stocks amidst the strong market recovery. Interestingly, six biopharma companies were the laggards, even as the industry delivered innovative and rapid solutions to combat the global public healt...
I continued to struggle in February, due to my overweight exposure to technology. However, due to my belief in the secular growth stories that propel the technology sector, I'm not losing any sleep at night. My dividend income stream increased by 3.1% in February, in spite of my A...
The combination of Mylan with Pfizer 's (NYSE: PFE) Upjohn unit to create Viatris (NASDAQ: VTRS) was supposed to create a cash-generating generic-drug company with the potential for future growth. Unfortunately the initial results for the combined company have been disappoin...
Viatris ([[VTRS]] -0.6%) (NASDAQ: VTRS) joined Kindeva Drug Delivery to announce the tentative FDA approval of budesonide/formoterol fumarate dihydrate products, the first generic version of Symbicort based on an abbreviated new drug application.Symbicort is indicated for certain pa...
Another $1.9T is set to hit the U.S. economy, including direct stimulus checks, after the Senate passed the COVID relief bill on party lines over the weekend.Goldman Sachs' Abby Joseph Cohen tells Bloomberg it's not just a stimulus package, but a "relief package that's getting us out of a hol...
Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol Milestone reinforces Viatris' commitment to complex products and ...
European authorities' antitrust probe will likely push the company to change its marketing practices, which allegedly hindered competitors from introducing generic versions of Teva's Copaxone®. With the recent commercialization of Belrapzo®, a superior substitute for Teva's ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 12:25:00 ET The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely. Three Motley Fool contributors think they've found surprisingly underrated pharmaceutical stocks to b...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...